Matches in SemOpenAlex for { <https://semopenalex.org/work/W2241843730> ?p ?o ?g. }
- W2241843730 endingPage "390" @default.
- W2241843730 startingPage "379" @default.
- W2241843730 abstract "Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their ability to prevent cancer treatment-induced bone loss (CTIBL) and reduce the risk of disease recurrence and metastasis. Treatment benefits have been reported but bisphosphonates do not currently have regulatory approval for either of these potential indications. This consensus paper provides a review of the evidence and offers guidance to breast cancer clinicians on the use of bisphosphonates in early breast cancer. Using the nominal group methodology for consensus, a systematic review of the literature was augmented by a workshop held in October 2014 for breast cancer and bone specialists to present and debate the available pre-clinical and clinical evidence for the use of adjuvant bisphosphonates. This was followed by a questionnaire to all members of the writing committee to identify areas of consensus. The panel recommended that bisphosphonates should be considered as part of routine clinical practice for the prevention of CTIBL in all patients with a T score of 18,000 patients supports clinically significant benefits of bisphosphonates on the development of bone metastases and breast cancer mortality in post-menopausal women or those receiving ovarian suppression therapy. Therefore, the panel recommends that bisphosphonates (either intravenous zoledronic acid or oral clodronate) are considered as part of the adjuvant breast cancer treatment in this population and the potential benefits and risks discussed with relevant patients." @default.
- W2241843730 created "2016-06-24" @default.
- W2241843730 creator A5000459869 @default.
- W2241843730 creator A5002979606 @default.
- W2241843730 creator A5003405177 @default.
- W2241843730 creator A5005887947 @default.
- W2241843730 creator A5007286394 @default.
- W2241843730 creator A5007727706 @default.
- W2241843730 creator A5012187098 @default.
- W2241843730 creator A5022190021 @default.
- W2241843730 creator A5027231412 @default.
- W2241843730 creator A5032611053 @default.
- W2241843730 creator A5033285318 @default.
- W2241843730 creator A5034630560 @default.
- W2241843730 creator A5034987953 @default.
- W2241843730 creator A5035054317 @default.
- W2241843730 creator A5035383163 @default.
- W2241843730 creator A5035387502 @default.
- W2241843730 creator A5045029537 @default.
- W2241843730 creator A5051306896 @default.
- W2241843730 creator A5051629490 @default.
- W2241843730 creator A5051980635 @default.
- W2241843730 creator A5053293171 @default.
- W2241843730 creator A5055977758 @default.
- W2241843730 creator A5057379395 @default.
- W2241843730 creator A5061698687 @default.
- W2241843730 creator A5070338465 @default.
- W2241843730 creator A5071571360 @default.
- W2241843730 creator A5078571816 @default.
- W2241843730 creator A5091765229 @default.
- W2241843730 date "2016-03-01" @default.
- W2241843730 modified "2023-10-17" @default.
- W2241843730 title "Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel" @default.
- W2241843730 cites W1800396987 @default.
- W2241843730 cites W1964611803 @default.
- W2241843730 cites W1964914901 @default.
- W2241843730 cites W1971400130 @default.
- W2241843730 cites W1971727102 @default.
- W2241843730 cites W1975344303 @default.
- W2241843730 cites W1982866065 @default.
- W2241843730 cites W1986544019 @default.
- W2241843730 cites W1989526399 @default.
- W2241843730 cites W1998403050 @default.
- W2241843730 cites W1998650954 @default.
- W2241843730 cites W1999899903 @default.
- W2241843730 cites W2000519574 @default.
- W2241843730 cites W2003692790 @default.
- W2241843730 cites W2003716766 @default.
- W2241843730 cites W2022904647 @default.
- W2241843730 cites W2025668946 @default.
- W2241843730 cites W2026113198 @default.
- W2241843730 cites W2026290443 @default.
- W2241843730 cites W2036181578 @default.
- W2241843730 cites W2039471900 @default.
- W2241843730 cites W2054012939 @default.
- W2241843730 cites W2054727157 @default.
- W2241843730 cites W2054923667 @default.
- W2241843730 cites W2055844573 @default.
- W2241843730 cites W2059327795 @default.
- W2241843730 cites W2062090814 @default.
- W2241843730 cites W2063992586 @default.
- W2241843730 cites W2067962376 @default.
- W2241843730 cites W2081333800 @default.
- W2241843730 cites W2081839216 @default.
- W2241843730 cites W2088014747 @default.
- W2241843730 cites W2096360340 @default.
- W2241843730 cites W2097410455 @default.
- W2241843730 cites W2103596289 @default.
- W2241843730 cites W2107118598 @default.
- W2241843730 cites W2109375600 @default.
- W2241843730 cites W2113581209 @default.
- W2241843730 cites W2114358979 @default.
- W2241843730 cites W2114581944 @default.
- W2241843730 cites W2117696515 @default.
- W2241843730 cites W2121099142 @default.
- W2241843730 cites W2122786185 @default.
- W2241843730 cites W2125014991 @default.
- W2241843730 cites W2126357214 @default.
- W2241843730 cites W2127286421 @default.
- W2241843730 cites W2127677509 @default.
- W2241843730 cites W2130251213 @default.
- W2241843730 cites W2131199058 @default.
- W2241843730 cites W2136646477 @default.
- W2241843730 cites W2137458001 @default.
- W2241843730 cites W2138691465 @default.
- W2241843730 cites W2139796029 @default.
- W2241843730 cites W2143939516 @default.
- W2241843730 cites W2146810449 @default.
- W2241843730 cites W2148096512 @default.
- W2241843730 cites W2152554716 @default.
- W2241843730 cites W2153711239 @default.
- W2241843730 cites W2154720522 @default.
- W2241843730 cites W2155937162 @default.
- W2241843730 cites W2158786144 @default.
- W2241843730 cites W2159436449 @default.
- W2241843730 cites W2160410818 @default.
- W2241843730 cites W2162269030 @default.
- W2241843730 cites W2163322699 @default.